Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.
Geeta Vemuri is a trailblazer. Following her time as a Managing Partner at Baxter Ventures and Baxalta Ventures, Vemuri founded Agent Capital, a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.
Longwood Fund closed the early-stage investment group’s fifth fund, which will be used to support the launch of new companies as well as the growth of startups in the life sciences space.
Blackstone Life Sciences V fund closed at its hard cap of $4.6 billion of total capital commitments, marking the largest life sciences private fund that raised to date.
Novo Nordisk is expanding the company’s presence in treating kidney disease with the acquisition of U.S.-based Corvidia Therapeutics for $2.1 billion.
Only a week after ARCH Venture Partners and Flagship Pioneering raised huge venture capital funds aimed at life sciences, Deerfield Management announced the closing of the Deerfield Healthcare Innovations Fund II with $840 million.
During the fight against COVID-19, the message from venture capital investors to biotechnology companies is mixed.
A first-of-its-kind investing collaboration is combining MPM Capital’s venture capital investment fundraising with Dana-Farber Cancer Institute’s philanthropic fundraising for cancer research.
Bio Buzz selected five women venture capitalists who are considered “trailblazing investors shaping the future of life science investing” in the BioCapital Hotbed Community.
After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.
